X0306 4 2021-07-06 0 0001662774 Cortexyme, Inc. CRTX 0001770786 Detke Michael J. C/O CORTEXYME, INC. 269 EAST GRAND AVE. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2021-07-06 4 M 0 12600 2.23 A 40861 D Common Stock 2021-07-06 4 S 0 32313 53.43 D 8548 D Common Stock 2021-07-06 4 S 0 8260 53.91 D 288 D Common Stock 2021-07-06 4 S 0 288 55.01 D 0 D Common Stock 2021-07-07 4 M 0 17400 2.23 A 17400 D Common Stock 2021-07-07 4 S 0 3934 53.24 D 13466 D Common Stock 2021-07-07 4 S 0 1648 54.37 D 11818 D Common Stock 2021-07-07 4 S 0 4353 55.38 D 7465 D Common Stock 2021-07-07 4 S 0 6942 56.27 D 523 D Common Stock 2021-07-07 4 S 0 523 56.99 D 0 D Stock Option (right to buy) 2.23 2021-07-06 4 M 0 12600 0.00 D 2028-11-27 Common Stock 12600 119752 D Stock Option (right to buy) 2.23 2021-07-07 4 M 0 17400 0.00 D 2028-11-27 Common Stock 17400 102352 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.69 to $53.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.71 to $54.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.745 to $53.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.75 to $54.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.79 to $55.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.81 to $57.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. /s/ Caryn Gordon McDowell, Attorney-in-Fact for Michael J. Detke, M.D. 2021-07-07